It is well documented that CD2+, CD56+, and CD34+ APL immunophenotypes are associated with lower overall survival (OS) rate, shorter remission, decreased incidence of remission, and increased incidence of early death, respectively [1–4]. Here, CD2 is linked to acute promyelocytic leukemia.